Table 3.

Factors associated with freedom from CNS progression (FFCNSP) after SRS treatment-1, Cox proportional hazards analysis.

Factor		Univariable				Multivariable
		HR	95 % CI lower	95 % CI upper	p-value	HR	95 % CI lower	95 % CI upper	p-value
Sex	Male	Reference				Reference
	Female	0.927	0.551	1.561	0.777	0.975	0.557	1.706	0.930
Driver oncogene	EGFR	Reference				Reference
	ALK	1.114	0.665	1.866	0.682	0.964	0.502	1.852	0.912
Age	continuous	0.988	0.967	1.011	0.275	0.984	0.959	1.010	0.218
Brain mets at stage IV presentation	No	Reference				Reference
	Yes	0.897	0.536	1.500	0.679	0.936	0.526	1.667	0.823
No. of brain mets treated with SRS treatment-1	Continuous	1.071	1.003	1.144	0.042	1.071	1.001	1.145	0.045
WBRT prior to SRS	No	Reference				Reference
	Yes	1.100	0.582	2.078	0.770	1.038	0.507	2.126	0.918
Receipt of next-generation TKI	No	Reference				Reference
	Yes	0.941	0.563	1.572	0.816	0.884	0.496	1.574	0.674